Rather than relying on population-based recommendations, clinicians should develop individualized treatment plans based on patient-specific risk factors and biomarkers
Eli Lilly intended to protect its tirzepatide patent aggressively, and any entity selling, compounding, or distributing unauthorized versions faced serious legal exposure
PlexusDx's microdose GLP-1 protocol, available at $129/mo, offers an alternative approach for those seeking slower titration to reduce acute GI disruption while still achieving therapeutic benefit
Tirzepatide also acts on the brain and white adipose tissue, which results in an enhanced feeling of fullness and increased production of appetite-suppressing mediators
Legal and Safety Information: This compound is supplied strictly for laboratory research purposes only
One-week continuous infusion of GLP-1 (737) improves glycemic control in NIDDM Diabetes 1996 45 (Suppl 2): 233A (abstract)